Cure8 trial brief
Distinguishing inflammation from irreversible fibrosis is a common clinical challenge in Crohn’s disease because it affects treatment choices (medical therapy versus surgery). Validated MRI biomarkers could improve noninvasive decision-making and earlier detection of progressive disease.
Adults with Crohn’s disease facing intestinal resection; clinicians and radiologists working with IBD imaging; researchers developing MRI biomarkers and mechanobiology of intestinal disease.
This ClinicalTrials.gov record describes an observational, recruiting study in France enrolling adults with Crohn’s disease who are undergoing planned intestinal resection.
Resected bowel specimens will undergo ex vivo multiparametric MRI (T1/T2 relaxometry, MR electrical properties tomography), magnetic resonance elastography, biophysical measurements (conductivity, permittivity, stiffness), and histopathology to map inflammation versus fibrosis and validate MRI-derived biomarkers.
The study is non-interventional for participants beyond standard surgical care; planned enrollment is 60 and primary outcomes are quantitative ex vivo MRI and electrical/mechanical property measurements taken on the day of surgery.
What the trial aims to do is link detailed ex vivo imaging and biophysical data with histology to improve interpretation of in vivo MRI biomarkers that could help distinguish inflammatory from fibrotic bowel changes in Crohn’s disease.
This summary is based on the trial registry record (ClinicalTrials.gov NCT07413653) and the provided study description and outcome measures; it does not represent independent review of study data or results.
This is an observational, ex vivo study using resected tissue and does not test a new drug or an in vivo intervention. Results would be hypothesis-generating and aimed at validating imaging biomarkers; the registry record does not report results yet.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study offers a validated tool to estimate risk of postoperative recurrence after ileocolonic resection and shows that postoperative biologic prophylaxis markedly lowers early endoscopic recurrence—information that...
Postoperative recurrence is common after intestinal resection for Crohn's disease, but clinicians currently lack reliable molecular biomarkers or validated models to predict who will relapse.
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
